Drug Trial Radar · NCT04886596
Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
Last checked: Nov 20, 2026Latest source record: Jul 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26,675
Actual
Start
May 25, 2021
Primary completion
Apr 11, 2022
Study completion May 31, 2024
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- May 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy of the RSVPreF3 OA investigational vaccine in preventing Lower Respiratory Tract Disease (LRTD) caused by RSV in adults ≥60 years of age following a single dose of the RSVPreF3 OA vaccine and following annual revaccination doses in Northern Hemisphere (NH) and in Southern Hemisphere (SH). This study will also assess if the vaccine is safe and induces an immune response.
Conditions
- Respiratory Syncytial Virus Infections
Interventions
PlaceboBiological
Placebo administered intramuscularly into the deltoid of the non-dominant arm at day 1 and before Season 2 to the Placebo Group, and before Season 2 to the participants of the RSVPreF3 Group, that are re-randomized to the RSV\_1 dose group.
RSVPreF3 OA vaccineBiological
RSVPreF3 OA vaccine administered intramuscularly into the deltoid of the non-dominant arm at Day 1 in the RSVPreF3 group, and before Season 2 to the participants of the RSVPreF3 group that are re-randomized to the RSV\_annual group.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated Lower Respiratory Tract Disease (LRTD) During the First Season Following a Single Dose of the RSVPreF3 OA VaccineTime frame: From Day 15 post-vaccination up to end of season 1 in the Northern Hemisphere (NH) [a median of approximately 6.7 months (6.9 months in NH and 3.5 months in Southern Hemisphere [SH])]
Locations
277 sites in 17 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Huntsville, Alabama
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Cerritos, California
GSK Investigational Site
Laguna Hills, California
GSK Investigational Site
Coral Gables, Florida
GSK Investigational Site
Fort Myers, Florida
GSK Investigational Site
Jacksonville, Florida
GSK Investigational Site
Lake City, Florida
GSK Investigational Site
Melbourne, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Pinellas Park, Florida
GSK Investigational Site
The Villages, Florida
GSK Investigational Site
Weeki Wachee, Florida
GSK Investigational Site
West Palm Beach, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Evansville, Indiana
GSK Investigational Site
Mishawaka, Indiana
GSK Investigational Site
El Dorado, Kansas
GSK Investigational Site
Newton, Kansas
GSK Investigational Site
Wichita, Kansas
GSK Investigational Site
Wichita, Kansas
GSK Investigational Site
Lexington, Kentucky
GSK Investigational Site
Rockville, Maryland
GSK Investigational Site
Richfield, Minnesota
GSK Investigational Site
Kansas City, Missouri
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Omaha, Nebraska
GSK Investigational Site
Henderson, Nevada
GSK Investigational Site
Binghamton, New York
GSK Investigational Site
Jamaica, New York
GSK Investigational Site
Rochester, New York
GSK Investigational Site
Hickory, North Carolina
GSK Investigational Site
Rocky Mount, North Carolina
GSK Investigational Site
Salisbury, North Carolina
GSK Investigational Site
Statesville, North Carolina
Showing 40 of 277 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.